Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22187761 | 1.00 | ALDH1A1 (0.51) | ALDH1A1KMT2AMEN1HDAC4POLB | |
| SCHEMBL14803619 | 0.84 | ALDH1A1 (0.64) | ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL19001131 | 0.83 | HRH3 (0.52) | KMT2AMEN1 | |
| SCHEMBL23328247 | 0.83 | HRH3 (0.52) | KMT2AMEN1 | |
| SCHEMBL19001066 | 0.83 | HRH3 (0.52) | KMT2AMEN1 | |
| SCHEMBL24243095 | 0.78 | NOTUM (0.54) | HDAC4POLB | |
| SCHEMBL12663092 | 0.78 | MBTD1 (0.61) | ALDH1A1HDAC4 | |
| SCHEMBL17127953 | 0.78 | MBTD1 (0.61) | ALDH1A1HDAC4 | |
| SCHEMBL24243040 | 0.76 | ESR1 (0.42) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL23510813 | 0.74 | KHK (0.47) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365196-B2 | FGFR inhibitor and application thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-06-21 | — | — | US | disclosed |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365196-B2 | FGFR inhibitor and application thereof | FGFR1, FGFR4, FGFR2 | ALDH1A1 748/4885KMT2A 3253/4885MEN1 4125/4885 |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | FGFR1, FGFR4, FGFR2 | ALDH1A1 642/4885KMT2A 3272/4885MEN1 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.